Fosamax and Osteonecrosis of the Jaw: Medical Literature on Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Occupational Exposure

The legacy of general health and science information has long provided foundational knowledge on medication safety and adverse effects, including those associated with bisphosphonate therapies like Fosamax. Traditionally, the focus has been on patient-level risks, emphasizing clinical outcomes and individual health management. However, a pivot is necessary to address occupational exposure concerns. In mass production environments, workers may encounter Fosamax or its precursors during manufacturing, handling, or packaging processes. This shifts the risk assessment from a purely clinical patient perspective to an industrial hygiene and occupational safety context. The concern now centers on potential inhalation, dermal contact, or accidental ingestion in the workplace, which could lead to similar adverse effects, including osteonecrosis of the jaw, albeit through different exposure pathways. This transition requires evaluating exposure limits, engineering controls, and personal protective equipment to mitigate risks. The legacy of general health information thus serves as a springboard to explore how these same compounds pose distinct challenges in occupational settings, where chronic low-level exposure or acute incidents may occur.

Bridging Patient and Worker Risk

The established medical literature on Fosamax-associated osteonecrosis of the jaw (ONJ) provides a critical foundation for understanding the potential risks in occupational settings. While the clinical context focuses on patients taking Fosamax for osteoporosis or other conditions, the same biological mechanisms—suppression of bone turnover, particularly in the jaw—apply to workers exposed to the drug or its precursors. This bridge concept connects the need for workplace surveillance and preventive measures, without delving into mechanistic details. It underscores the importance of adapting health knowledge to protect workers in mass production contexts, where exposure pathways differ but the adverse outcome may be similar.

Fosamax and Osteonecrosis of the Jaw: Clinical Evidence

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ involves areas of exposed bone in the mandible or maxilla that persist for more than eight weeks, often accompanied by pain, swelling, and infection. Diagnosis is primarily clinical, based on visual examination and history of bisphosphonate use, with imaging such as panoramic radiographs or CT scans used to assess the extent of bone involvement.

Mechanisms and Risk Factors

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current understanding points to the drug's potent inhibition of osteoclast activity, which suppresses bone turnover. The jawbone has unique characteristics, including high remodeling rates and frequent microtrauma from mastication, making it particularly susceptible to bisphosphonate-related complications. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that the jawbone's structural and cellular environment may predispose it to ONJ when bone remodeling is excessively suppressed by bisphosphonates like Fosamax. Risk factors for ONJ in patients taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Temporal Relationship and Causation

The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In a cohort study among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This indicates that while the relative risk increases with longer exposure, the absolute risk remains small. Regarding adequacy of warnings, the prescribing information for Fosamax includes a specific warning under section 5.4 titled 'Osteonecrosis of the Jaw,' which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also notes that most patients had relief of symptoms after stopping the drug, and a subset had recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Additionally, the label for Fosamax Plus D similarly describes ONJ risk factors and the potential benefit of treatment discontinuation before invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Implications for Occupational Exposure

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and ONJ onset, excluding other potential causes such as cancer or concurrent medications, and documenting the clinical course. The evidence shows that ONJ risk is associated with duration of bisphosphonate use, with higher relative risks after prolonged exposure (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, the absolute risk remains low, and the condition is rare in osteoporosis patients. For patients who develop ONJ, discontinuation of Fosamax may lead to symptom relief, though some may experience recurrence if rechallenged (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The decision to continue or stop therapy should be made on an individual basis, weighing the benefits of fracture prevention against the risk of ONJ. In summary, Fosamax is associated with a rare but recognized risk of ONJ, with onset ranging from days to months after initiation and increasing with longer use. The prescribing information includes warnings about this risk and recommendations for management, such as considering discontinuation before dental procedures. Mechanistic understanding points to suppressed bone turnover in the jaw, and clinical data confirm a dose-response relationship with exposure duration. Patients and clinicians should be aware of these factors when considering Fosamax therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that inhibits bone resorption. A recognized adverse effect is osteonecrosis of the jaw (ONJ), characterized by exposed non-healing bone in the jaw. The risk is associated with duration of use, with higher relative risks after prolonged exposure, though absolute risk remains low (https://pubmed.ncbi.nlm.nih.gov/39400702/).

How soon after starting Fosamax can ONJ occur?

The time to onset of ONJ symptoms can range from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Risk increases with longer exposure.

What are the risk factors for developing ONJ while on Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.